Rubin of Johns Hopkins Medical Institutions in Baltimore.
What does JHMI stand for?
JHMI stands for Johns Hopkins Medical Institution
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
- Organizations, NGOs, schools, universities, etc.
See other definitions of JHMI
- Johns Hopkins Medicine Center for Information Services
- Jewish Hospital Medical Center South (Louisville, KY)
- Joint Helmet Mounted Cueing System
- Jackson Hole Music Experience (Jackson, WY)
- JH Media and Entertainment (UK)
- Joint Health-Care Management Engineering Team
- Jackson Hole Mountain Guides
- J. Hillis Miller Health Center (University of Florida, Gainesville, FL)
- Jesus Heals Ministries International
- Jimmy Hodges Ministries International (est. 1986; Oklahoma City, OK)
- Johns Hopkins Medicine Institutional Review Board
- Johns Hopkins Medical Laboratories (Johns Hopkins University; pathology)
- Junior Honors Medical Program
- Jackson Hole Mountain Resort
- June Hancock Mesothelioma Research Fund
- Johns Hopkins Malaria Research Institute
- Jackson Heights Middle School (Oviedo, FL)
- Joe Harrison Motor Sports (San Antonia, TX)
- John Hanson Middle School (Waldorf, MD)
- Johns Hopkins Medical Services Corporation
Samples in periodicals archive:
In another study from The Johns Hopkins Medical Institutions in Baltimore, subjects were randomly assigned to one of three diets, which were given for three weeks.
In a separate study from the Johns Hopkins Medical Institutions in Baltimore, researchers found a higher antioxidant capacity in 83 people who ate eight to ten servings of fruits and vegetables a day than in 40 others who ate fewer servings.
Brodsky of Johns Hopkins Medical Institutions in Baltimore in the same issue of JAMA.
Kellogg Parsons of Johns Hopkins Medical Institutions in Baltimore and his colleagues used nearly 40 years of test results from 794 men to assess the relationship between prostate cancer and variations in blood concentrations of testosterone.
When analyzing data provided by the participants, Elizabeth Platz of Johns Hopkins Medical Institutions in Baltimore and her colleagues at Harvard University found that men who had been taking cholesterol-lowering drugs were only half as likely to develop potentially lethal prostate cancer as were men not taking such medications.